Inclinix

About Inclinix

Established in 1999 originally as PharmaTech Solutions, Inclinix has carved a specialized niche within the contract research organization (CRO) sector by focusing on patient enrollment for clinical trials. The firm provides its services to a client base composed of pharmaceutical, biotechnology, and medical device organizations. A significant development in the company's trajectory occurred in 2006 when it merged with Realinterface Expert Systems, Inc. (RESI), a Maryland-based software company. This merger led to the integration of RESI's patient screening technology and the adoption of the name Inclinix, which was the title of the acquired clinical trial recruiting and management application.

The company's growth was further accelerated by a $10 million investment from private equity firm Frontier Capital in 2008, which was aimed at enhancing its patient-enrolment processes and technologies. This financial backing set the stage for another pivotal moment in 2012 when a consortium of investors, once again led by Frontier Capital, funded the strategic merger of Inclinix with PMG Research. This transaction resulted in the formation of Inclinix-PMG Holdings and created an entity that combined patient recruitment expertise with the operational capabilities of a network of clinical research sites. The leadership of the merged entity was composed of J. Tobin Geatz as President and CEO, and Jeffrey Reiniche as CFO.

Inclinix's business model is centered on delivering customized, site-focused patient recruitment solutions for Phase I-IV clinical trials. This involves a multi-faceted approach that includes identifying and qualifying suitable patients for trials, as well as providing support to the investigative sites conducting the research. The company's service portfolio encompasses a range of activities such as enrollment feasibility assessments, investigator recruitment, and site support. By combining an in-field approach with targeted patient outreach, the company develops effective enrollment strategies. This integrated model, which was unconventional for a CRO at the time, aimed to provide sponsors and CROs with a bundled service that included both world-class research sites and proficient patient recruiting.